Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Were Downgraded Today by BidaskScore

Rhythm Pharmaceuticals (NASDAQ:RYTM) Receives a Downgrade

BidaskScore downgraded Rhythm Pharmaceuticals (NASDAQ:RYTM) shares to a Sell rating in a note revealed to investors and clients today.

The stock increased 0.46% or $0.09 during the last trading session, reaching $19.62. About 110,944 shares traded. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) has declined 35.49% since October 10, 2018 and is downtrending. It has underperformed by 35.49% the S&P500.

Analysts await Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) to report earnings on November, 8. They expect $-1.00 earnings per share, down 92.31 % or $0.48 from last year’s $-0.52 per share. After $-1.24 actual earnings per share reported by Rhythm Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -19.35 % EPS growth.

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. The company has market cap of $677.18 million. The Company’s lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alstr??m syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. It currently has negative earnings. The firm was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015.

More notable recent Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) news were published by: Seekingalpha.com which released: “Rhythm Pharma gets orphan status for setmelanotide – Seeking Alpha” on September 19, 2019, also Nasdaq.com with their article: “Health Care Sector Update for 03/20/2019: CORV,NVRO,MTFB,BHC,BHC.TO – Nasdaq” published on March 20, 2019, Seekingalpha.com published: “Rhythm Pharmaceuticals And Setmelanotide In Rare Obesity – Seeking Alpha” on October 08, 2019. More interesting news about Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) were released by: Globenewswire.com and their article: “Rhythm Pharmaceuticals Reports First Quarter 2019 Financial Results – GlobeNewswire” published on May 03, 2019 as well as Globenewswire.com‘s news article titled: “Rhythm Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference – GlobeNewswire” with publication date: May 30, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.